ATRC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AtriCure Inc (ATRC) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company has shown revenue growth, its net income and EPS have significantly declined. The technical indicators suggest a bearish trend, and there are no strong proprietary trading signals or recent positive news to support immediate entry. Analysts remain cautiously optimistic but have lowered price targets due to competitive pressures. Holding off for now is advisable until stronger catalysts emerge.
The technical indicators show a bearish trend with SMA_200 > SMA_20 > SMA_5. MACD is positive but contracting, and RSI is neutral at 49.672. Key support is at 27.616, and resistance is at 30.061. The stock's recent performance suggests limited short-term upside potential.
Analysts maintain Buy ratings with some optimism about the company's competitive moat and product pipeline.
Net income and EPS have dropped significantly (-111.28% and -112.12% YoY, respectively). Analysts have lowered price targets due to competitive threats from Edwards Lifesciences and Medtronic. Oppenheimer and JPMorgan downgraded the stock, citing long-term competitive risks.
In Q4 2025, revenue increased to $140.5M (up 13.05% YoY), but net income dropped to $1.756M (-111.28% YoY), and EPS fell to $0.04 (-112.12% YoY). Gross margin improved slightly to 74.97%.
Analysts are mixed but leaning positive. Freedom Capital initiated a Buy rating with a $43 price target. However, several firms, including JPMorgan and Oppenheimer, downgraded the stock due to competitive risks. Price targets range from $36 to $55, with a median target of $47.25.
